Municipal police support for harm reduction services in officer-led referrals of people who inject drugs in Tijuana, Mexico

Pieter Baker, Jaime Arredondo, Annick Borquez, Erika Clairgue, Maria L Mittal, Mario Morales, Teresita Rocha-Jimenez, Richard Garfein, Eyal Oren, Eileen Pitpitan, Steffanie A Strathdee, Leo Beletsky, Javier A Cepeda, Pieter Baker, Jaime Arredondo, Annick Borquez, Erika Clairgue, Maria L Mittal, Mario Morales, Teresita Rocha-Jimenez, Richard Garfein, Eyal Oren, Eileen Pitpitan, Steffanie A Strathdee, Leo Beletsky, Javier A Cepeda

Abstract

Background: Police constitute a structural determinant of health and HIV risk of people who inject drugs (PWID), and negative encounters with law enforcement present significant barriers to PWID access to harm reduction services. Conversely, police may facilitate access via officer-led referrals, potentiating prevention of HIV, overdose, and drug-related harms. We aimed to identify police characteristics associated with support for officer-led referrals to addiction treatment services and syringe service programs (SSP). We hypothesized that officers who believe harm reduction services are contradictory to policing priorities in terms of safety and crime reduction will be less likely to support police referrals.

Methods: Between January and June 2018, police officers (n = 305) in Tijuana, Mexico, completed self-administered surveys about referrals to harm reduction services during the 24-month follow-up visit as part of the SHIELD police training and longitudinal cohort study. Log-binomial regression was used to estimate adjusted prevalence ratios and model policing characteristics and attitudes related to officers' support for including addiction treatment and SSP in referrals.

Results: Respondents were primarily male (89%), patrol officers (86%) with a median age of 38 years (IQR 33-43). Overall, 89% endorsed referral to addiction services, whereas 53% endorsed SSP as acceptable targets of referrals. Officers endorsing addiction services were less likely to be assigned to high drug use districts (adjusted prevalence ratio [APR] = 0.50, 95% CI 0.24, 1.08) and more likely to agree that methadone programs reduce crime (APR = 4.66, 95% CI 2.05, 9.18) than officers who did not support addiction services. Officers endorsing SSPs were younger (adjusted prevalence ratio [APR] = 0.96 95% CI 0.93, 0.98), less likely to be assigned to high drug use districts (APR = 0.50, 95% CI 0.29, 0.87), more likely to believe that methadone programs reduce crime (APR = 2.43, 95% CI 1.30, 4.55), and less likely to believe that SSPs increase risk of needlestick injury for police (APR = 0.44, 0.27, 0.71).

Conclusions: Beliefs related to the occupational impact of harm reduction services in terms of officer safety and crime reduction are associated with support for referral to related harm reduction services. Efforts to deflect PWID from carceral systems toward harm reduction by frontline police should include measures to improve officer knowledge and attitudes about harm reduction services as they relate to occupational safety and law enforcement priorities.

Trial registration: NCT02444403.

Keywords: Addiction; HIV; Harm reduction; Law enforcement; People who use drugs; Police; Referral; Syringe service program.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

References

    1. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths-United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;64(50–51):1378–1382. doi: 10.15585/mmwr.mm6450a3.
    1. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths—United States, 2013–2017. MMWR Morb Mortal Wkly Rep. 2018;67(5152):1419–1427. doi: 10.15585/mmwr.mm675152e1.
    1. Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N, et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction. 2014;109(8):1320–1333. doi: 10.1111/add.12551.
    1. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192–e1207. doi: 10.1016/S2214-109X(17)30375-3.
    1. Peters PJ, Pontones P, Hoover KW, Patel MR, Galang RR, Shields J, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. N Engl J Med. 2016;375(3):229–239. doi: 10.1056/NEJMoa1515195.
    1. Wakeman SE, Green TC, Rich J. An overdose surge will compound the COVID-19 pandemic if urgent action is not taken. Nat Med. 2020;26(6):819–820. doi: 10.1038/s41591-020-0898-0.
    1. Croxford S, Emanuel E, Ibitoye A, Njoroge J, Edmundson C, Bardsley M, et al. Preliminary indications of the burden of COVID-19 among people who inject drugs in England and Northern Ireland and the impact on access to health and harm reduction services. Public Health. 2021;192:8–11. doi: 10.1016/j.puhe.2021.01.004.
    1. Iversen J, Sabin K, Chang J, Morgan Thomas R, Prestage G, Strathdee SA, et al. COVID-19, HIV and key populations: cross-cutting issues and the need for population-specific responses. J Int AIDS Soc. 2020;23(10):e25632. doi: 10.1002/jia2.25632.
    1. Vasylyeva TI, Smyrnov P, Strathdee S, Friedman SR. Challenges posed by COVID-19 to people who inject drugs and lessons from other outbreaks. J Int AIDS Soc. 2020;23(7):e25583. doi: 10.1002/jia2.25583.
    1. Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5(12):e1208–e1220. doi: 10.1016/S2214-109X(17)30373-X.
    1. Fernandes RM, Cary M, Duarte G, Jesus G, Alarcão J, Torre C, et al. Effectiveness of needle and syringe Programmes in people who inject drugs—An overview of systematic reviews. BMC Public Health. 2017;17(1):309. doi: 10.1186/s12889-017-4210-2.
    1. Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:i1550. doi: 10.1136/bmj.j1550.
    1. Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van Velzen E, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):235–248. doi: 10.1093/ije/dyt243.
    1. Macarthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345(oct03 3):e5945-e. doi: 10.1136/bmj.e5945.
    1. Wilson DP, Donald B, Shattock AJ, Wilson D, Fraser-Hurt N. The cost-effectiveness of harm reduction. Int J Drug Policy. 2015;26(Suppl 1):S5–11. doi: 10.1016/j.drugpo.2014.11.007.
    1. Ayon S, Ndimbii J, Jeneby F, Abdulrahman T, Mlewa O, Wang B, et al. Barriers and facilitators of access to HIV, harm reduction and sexual and reproductive health services by women who inject drugs: role of community-based outreach and drop-in centers. AIDS Care. 2018;30(4):480–487. doi: 10.1080/09540121.2017.1394965.
    1. Bazzi AR, Syvertsen JL, Rolon ML, Martinez G, Rangel G, Vera A, et al. Social and structural challenges to drug cessation among couples in Northern Mexico: implications for drug treatment in underserved communities. J Subst Abuse Treat. 2016;61:26–33. doi: 10.1016/j.jsat.2015.08.007.
    1. Syvertsen J, Pollini RA, Lozada R, Vera A, Rangel G, Strathdee SA. Managing la malilla: Exploring drug treatment experiences among injection drug users in Tijuana, Mexico, and their implications for drug law reform. Int J Drug Policy. 2010;21(6):459–465. doi: 10.1016/j.drugpo.2010.06.006.
    1. Cepeda J, Burgos L, Kahn J, Padilla R, Meza P, Segovia L, et al. Evaluating the impact of global fund withdrawal on needle and syringe provision, cost and use among people who inject drugs in Tijuana, Mexico: A costing analysis. BMJ Open. 2019;9:e026298. doi: 10.1136/bmjopen-2018-026298.
    1. Burgos JL, Cepeda JA, Kahn JG, Mittal ML, Meza E, Lazos RRP, et al. Cost of provision of opioid substitution therapy provision in Tijuana, Mexico. Harm Reduct J. 2018;15(1):28. doi: 10.1186/s12954-018-0234-x.
    1. Allen S, Ruiz M, O'Rourke A. How far will they go? Assessing the travel distance of current and former drug users to access harm reduction services. Harm Reduct J. 2015;12:3. doi: 10.1186/s12954-015-0043-4.
    1. Brouwer KC, Lozada R, Cornelius WA, Firestone Cruz M, Magis-Rodriguez C, Zuniga de Nuncio ML, et al. Deportation along the U.S.-Mexico border: its relation to drug use patterns and accessing care. J Immigr Minor Health. 2009;11(1):1–6. doi: 10.1007/s10903-008-9119-5.
    1. Ojeda VD, Robertson AM, Hiller SP, Lozada R, Cornelius W, Palinkas LA, et al. A qualitative view of drug use behaviors of Mexican male injection drug users deported from the United States. J Urban Health. 2011;88(1):104–117. doi: 10.1007/s11524-010-9508-7.
    1. Earnshaw V, Smith L, Copenhaver M. Drug addiction stigma in the context of methadone maintenance therapy: an investigation into understudied sources of stigma. Int J Ment Health Addict. 2013;11(1):110–122. doi: 10.1007/s11469-012-9402-5.
    1. Philbin MM, Lozada R, Zuniga ML, Mantsios A, Case P, Magis-Rodriguez C, et al. A qualitative assessment of stakeholder perceptions and socio-cultural influences on the acceptability of harm reduction programs in Tijuana. Mexico Harm Reduct J. 2008;5:36. doi: 10.1186/1477-7517-5-36.
    1. Beletsky L, Heller D, Jenness SM, Neaigus A, Gelpi-Acosta C, Hagan H. Syringe access, syringe sharing, and police encounters among people who inject drugs in New York City: a community-level perspective. Int J Drug Policy. 2014;25(1):105–111. doi: 10.1016/j.drugpo.2013.06.005.
    1. Werb D, Wagner KD, Beletsky L, Gonzalez-Zuniga P, Rangel G, Strathdee SA. Police bribery and access to methadone maintenance therapy within the context of drug policy reform in Tijuana. Mexico Drug Alcohol Dependence. 2015;148:221–225. doi: 10.1016/j.drugalcdep.2015.01.011.
    1. Baker P, Beletsky L, Avalos L, Venegas C, Rivera C, Strathdee SA, et al. Policing practices and risk of HIV infection among people who inject drugs. Epidemiol Rev. 2020;42:27–40. doi: 10.1093/epirev/mxaa010.
    1. DeBeck K, Cheng T, Montaner JS, Beyrer C, Elliott R, Sherman S, et al. HIV and the criminalisation of drug use among people who inject drugs: a systematic review. Lancet HIV. 2017;4(8):e357–e374. doi: 10.1016/S2352-3018(17)30073-5.
    1. Iroh PA, Mayo H, Nijhawan AE. The HIV care cascade before, during, and after incarceration: a systematic review and data synthesis. Am J Public Health. 2015;105(7):e5–16. doi: 10.2105/AJPH.2015.302635.
    1. Stone J, Fraser H, Lim AG, Walker JG, Ward Z, MacGregor L, et al. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2018;18(12):1397–1409. doi: 10.1016/S1473-3099(18)30469-9.
    1. Rhodes T. The ‘risk environment’: a framework for understanding and reducing drug-related harm. Int J Drug Policy. 2002;13(2):85–94. doi: 10.1016/S0955-3959(02)00007-5.
    1. Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sci Med. 2005;61(5):1026–1044. doi: 10.1016/j.socscimed.2004.12.024.
    1. Strathdee SA, Lozada R, Pollini RA, Brouwer KC, Mantsios A, Abramovitz DA, et al. Individual, social, and environmental influences associated with HIV infection among injection drug users in Tijuana, Mexico. J Acquir Immune Defic Syndr. 2008;47(3):369–376. doi: 10.1097/QAI.0b013e318160d5ae.
    1. Werb D, Strathdee SA, Vera A, Arredondo J, Beletsky L, Gonzalez-Zuniga P, et al. Spatial patterns of arrests, police assault and addiction treatment center locations in Tijuana. Mexico Addict. 2016;111(7):1246–1256. doi: 10.1111/add.13350.
    1. Kutsa O, Marcus R, Bojko MJ, Zelenev A, Mazhnaya A, Dvoriak S, et al. Factors associated with physical and sexual violence by police among people who inject drugs in Ukraine: implications for retention on opioid agonist therapy. J Int AIDS Soc. 2016;19(4 Suppl 3):20897. doi: 10.7448/IAS.19.4.20897.
    1. Hayashi K, Ti L, Kaplan K, Suwannawong P, Wood E, Kerr T. Police interference with methadone treatment in Bangkok. Thailand Int J Drug Policy. 2015;26(1):112–115. doi: 10.1016/j.drugpo.2014.08.009.
    1. Fairbairn N, Kaplan K, Hayashi K, Suwannawong P, Lai C, Wood E, et al. Reports of evidence planting by police among a community-based sample of injection drug users in Bangkok, Thailand. BMC Int Health Human Rights. 2009;9:24. doi: 10.1186/1472-698X-9-24.
    1. Lunze K, Raj A, Cheng DM, Quinn EK, Bridden C, Blokhina E, et al. Punitive policing and associated substance use risks among HIV-positive people in Russia who inject drugs. J Int AIDS Soc. 2014;17(1):19043. doi: 10.7448/IAS.17.1.19043.
    1. Rafful C, Orozco R, Rangel G, Davidson P, Werb D, Beletsky L, et al. Increased non-fatal overdose risk associated with involuntary drug treatment in a longitudinal study with people who inject drugs. Addiction. 2018;113(6):1056–1063. doi: 10.1111/add.14159.
    1. Ospina-Escobar A, Magis-Rodríguez C, Juárez F, Werb D, Bautista Arredondo S, Carreón R, et al. Comparing risk environments for HIV among people who inject drugs from three cities in Northern Mexico. Harm Reduct J. 2018;15(1):27. doi: 10.1186/s12954-018-0225-y.
    1. Borquez A, Garfein RS, Abramovitz D, Liu L, Beletsky L, Werb D, et al. Prevalence and correlates of injecting with visitors from the United States among people who inject drugs in Tijuana, Mexico. J Immigr Minor Health. 2019;21:1200–1207. doi: 10.1007/s10903-019-00868-8.
    1. Brouwer KC, Strathdee SA, Magis-Rodríguez C, Bravo-García E, Gayet C, Patterson TL, et al. Estimated numbers of men and women infected with HIV/AIDS in Tijuana, Mexico. J Urban Health. 2006;83(2):299–307. doi: 10.1007/s11524-005-9027-0.
    1. Bucardo J, Brouwer KC, Magis-Rodriguez C, Ramos R, Fraga M, Perez SG, et al. Historical trends in the production and consumption of illicit drugs in Mexico: implications for the prevention of blood borne infections. Drug Alcohol Depend. 2005;79(3):281–293. doi: 10.1016/j.drugalcdep.2005.02.003.
    1. Strathdee SA, Magis-Rodriguez C, Mays VM, Jimenez R, Patterson TL. The emerging HIV epidemic on the Mexico-U.S. border: an international case study characterizing the role of epidemiology in surveillance and response. Ann Epidemiol. 2012;22(6):426–438. doi: 10.1016/j.annepidem.2012.04.002.
    1. Harvey-Vera AY, Gonzalez-Zuniga P, Vargas-Ojeda AC, Medina-Mora ME, Magis-Rodriguez CL, Wagner K, et al. Risk of violence in drug rehabilitation centers: perceptions of people who inject drugs in Tijuana. Mexico Subst Abuse Treat Prev Policy. 2016;11:5. doi: 10.1186/s13011-015-0044-z.
    1. Morales M, Rafful C, Baker P, Arredondo J, Kang S, Mittal ML, et al. “Pick up anything that moves”: a qualitative analysis of a police crackdown against people who use drugs in Tijuana, Mexico. Health Justice. 2020;8(1):9. doi: 10.1186/s40352-020-00111-9.
    1. Morales M, Rafful C, Gaines TL, Cepeda JA, Abramovitz D, Artamonova I, et al. Factors associated with extrajudicial arrest for syringe possession: results of a department-wide survey of municipal police in Tijuana, Mexico. BMC Int Health Hum Rights. 2018;18(1):36. doi: 10.1186/s12914-018-0175-1.
    1. Philbin M, Pollini RA, Ramos R, Lozada R, Brouwer KC, Ramos ME, et al. Shooting gallery attendance among IDUs in Tijuana and Ciudad Juarez, Mexico: Correlates, Prevention Opportunities, and the role of the environment. AIDS Behav. 2008;12(4):552–560. doi: 10.1007/s10461-008-9372-6.
    1. Robertson AM, Garfein RS, Wagner KD, Mehta SR, Magis-Rodriguez C, Cuevas-Mota J, et al. Evaluating the impact of Mexico's drug policy reforms on people who inject drugs in Tijuana, B.C., Mexico, and San Diego, CA, United States: a binational mixed methods research agenda. Harm Reduct J. 2014;11:4. doi: 10.1186/1477-7517-11-4.
    1. Wood EF, Werb D, Beletsky L, Rangel G, Cuevas Mota J, Garfein RS, et al. Differential experiences of Mexican policing by people who inject drugs residing in Tijuana and San Diego. Int J Drug Policy. 2017;41:132–139. doi: 10.1016/j.drugpo.2016.12.010.
    1. Collins SE, Lonczak HS, Clifasefi SL. Seattle’s Law Enforcement Assisted Diversion (LEAD): Program effects on recidivism outcomes. Eval Program Plann. 2017;64:49–56. doi: 10.1016/j.evalprogplan.2017.05.008.
    1. Khorasheh T, Naraine R, Watson TM, Wright A, Kallio N, Strike C. A scoping review of harm reduction training for police officers. Drug Alcohol Rev. 2019;38(2):131–150. doi: 10.1111/dar.12904.
    1. Strathdee SA, Arredondo J, Rocha T, Abramovitz D, Rolon ML, Patiño Mandujano E, et al. A police education programme to integrate occupational safety and HIV prevention: protocol for a modified stepped-wedge study design with parallel prospective cohorts to assess behavioural outcomes. BMJ Open. 2015;5(8):e008958. doi: 10.1136/bmjopen-2015-008958.
    1. Hagger MS, Chatzisarantis NLD. The trans-contextual model of autonomous motivation in education. Rev Educ Res. 2016;86(2):360–407. doi: 10.3102/0034654315585005.
    1. Rocha-Jiménez T, Mittal ML, Artamonova I, Baker P, Cepeda J, Morales M, et al. The role of gender in the health and human rights practices of police: the SHIELD study in Tijuana. Mexico Health Hum Rights. 2019;21(1):227–238.
    1. Arredondo J, Beletsky L, Baker P, Abramovitz D, Artamonova I, Clairgue E, et al. Interactive versus video-based training of police to communicate syringe legality to people who inject drugs: the SHIELD study, Mexico, 2015–2016. Am J Public Health. 2019;109(6):921–926. doi: 10.2105/AJPH.2019.305030.
    1. Beletsky L, Abramovitz D, Arredondo J, Baker P, Artamonova I, Marotta P, et al. Addressing police occupational safety during an opioid crisis: the syringe threat and injury correlates (STIC) score. J Occup Environ Med. 2020;62(1):46–51. doi: 10.1097/JOM.0000000000001754.
    1. Mittal ML, Artamonova I, Baker P, Strathdee SA, Cepeda J, Banuelos A, et al. Improving police conceptual knowledge of Mexico's law on cannabis possession: findings from an assessment of a police education program. Am J Addict. 2018;27(8):608–611. doi: 10.1111/ajad.12827.
    1. Beletsky L, Thomas R, Shumskaya N, Artamonova I, Smelyanskaya M. Police education as a component of national HIV response: lessons from Kyrgyzstan. Drug Alcohol Depend. 2013;132(Suppl 1):S48–52. doi: 10.1016/j.drugalcdep.2013.06.027.
    1. Olgin GK, Bórquez A, Baker P, Clairgue E, Morales M, Bañuelos A, et al. Preferences and acceptability of law enforcement initiated referrals for people who inject drugs: a mixed methods analysis. Substance Abuse Treat Prevent Policy. 2020;15(1):75. doi: 10.1186/s13011-020-00319-w.
    1. Strike C, Watson TM, Altenberg J, Barnaby L, Bayoumi AM, Challacombe L, et al. Challenges, skepticism, and recommendations from police about working in collaboration with supervised consumption services. Subst Use Misuse. 2020;55(12):1919–1924. doi: 10.1080/10826084.2020.1781177.
    1. Peterson SA, Wolkow AP, Lockley SW, O'Brien CS, Qadri S, Sullivan JP, et al. Associations between shift work characteristics, shift work schedules, sleep and burnout in North American police officers: a cross-sectional study. BMJ Open. 2019;9(11):e030302. doi: 10.1136/bmjopen-2019-030302.
    1. Sightes E, Ray B, Paquet SR, Bailey K, Huynh P, Weintraut M. Police officer attitudes towards syringe services programming. Drug Alcohol Depend. 2019;205:107617. doi: 10.1016/j.drugalcdep.2019.107617.
    1. Morales M, Baker P, Rafful C, Mittal M, Rocha T, Clairgue E, et al. Conflicting laws and priorities as drug policy implementation barriers: a qualitative analysis of police perspectives in Tijuana, Mexico. J Drug Policy Anal. 2020;12:10.
    1. Schiff DM, Drainoni ML, Weinstein ZM, Chan L, Bair-Merritt M, Rosenbloom D. A police-led addiction treatment referral program in Gloucester, MA: Implementation and participants' experiences. J Subst Abuse Treat. 2017;82:41–47. doi: 10.1016/j.jsat.2017.09.003.
    1. Christopher PP, Anderson B, Stein MD. Civil commitment experiences among opioid users. Drug Alcohol Depend. 2018;193:137–141. doi: 10.1016/j.drugalcdep.2018.10.001.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera